Why Did CorMedix Plunge 11.3% Ahead of Q1 Earnings?

On May 6, 2025, CorMedix's stock experienced a significant drop of 11.3% in pre-market trading, reflecting investor sentiment ahead of its Q1 2025 earnings announcement.

CorMedix is scheduled to release its first-quarter 2025 financial results and provide a corporate update on May 6, 2025. This announcement is highly anticipated as it will offer insights into the company's revenue performance and market trends.

RBC Capital has maintained a bullish stance on CorMedix, citing the company's preliminary Q1 2025 revenue figures as reassuring for near-term prospects. This positive outlook from a major financial institution has likely influenced investor confidence and market expectations.

Investors are closely monitoring CorMedix's earnings report, which is expected to show a 196% growth in earnings per share (EPS). This substantial growth projection has contributed to the heightened interest and potential volatility in the stock's performance.